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Purpose: To prospectively determine diagnostic performance and
safety of contrast material–enhanced (CE) magnetic reso-
nance (MR) angiography with 0.1 mmol per kilogram of
body weight gadobenate dimeglumine for depiction of sig-
nificant steno-occlusive disease (51% stenosis) of renal
arteries, with digital subtraction angiography (DSA) as
reference standard.
Materials and
Methods:
This multicenter study was approved by local institutional re-
view boards; all patients provided written informed consent.
Patient enrollment and examination at centers in the United
States complied with HIPAA. Two hundred ninety-three pa-
tients (154men, 139women;meanage, 61.0 years)with severe
hypertension (82.2%), progressive renal failure (11.3%), and
suspected renal artery stenosis (6.5%) underwent CE MR an-
giography with three-dimensional spoiled gradient-echo se-
quences after administration of 0.1 mmol/kg gadobenate dime-
glumine at 2 mL/sec. Anteroposterior and oblique DSA was
performed in 268 (91.5%) patients. Three independent blinded
reviewers evaluated CE MR angiographic images. Sensitivity,
specificity, and accuracy of CEMR angiography for detection of
significant steno-occlusive disease (51%vessel lumen narrow-
ing) were determined at segment (main renal artery) and pa-
tient levels. Positive and negative predictive values and positive
and negative likelihood ratios were determined. Interobserver
agreement was analyzed with generalized  statistics. A safety
evaluation (clinical examination, electrocardiogram, blood and
urine analysis, monitoring for adverse events) was performed.
Results: Of 268 patients, 178 who were evaluated with MR angiog-
raphy and DSA had significant steno-occlusive disease of
renal arteries at DSA. Sensitivity, specificity, and accuracy
of CE MR angiography for detection of 51% or greater
stenosis or occlusion were 60.1%–84.1%, 89.4%–94.7%,
and 80.4%–86.9%, respectively, at segment level. Similar
values were obtained for predictive values and for patient-
level analyses. Few CE MR angiographic examinations
(1.9%–2.8%) were technically inadequate. Interobserver
agreement for detection of significant steno-occlusive dis-
ease was good (79.9% agreement;   0.69). No safety
concerns were noted.
Conclusion: CE MR angiography performed with 0.1 mmol/kg gado-
benate dimeglumine, compared with DSA, is safe and
provides good sensitivity, specificity, and accuracy for de-
tection of significant renal artery steno-occlusive disease.
 RSNA, 2008
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Recognition of individuals with pos-sible renal artery stenosis (RAS)is widely considered an important
clinical application of contrast material–
enhanced (CE) magnetic resonance
(MR) angiography (1–21); the tech-
nique has been shown to offer superior
accuracy compared with minimally in-
vasive ultrasonographic (US) (22,23),
scintigraphic (13,22), and unenhanced
MR angiographic (2,8) techniques and
accuracy comparable to that of the
more invasive and riskier (24,25) con-
ventional x-ray angiography (2–9,11,
12,14–16,23,26–28). Although compa-
rable sensitivity and specificity for the
detection of hemodynamically signifi-
cant stenosis has been demonstrated
for multi–detector row computed to-
mography (CT) (29), disadvantages of
this approach are the requirements for
ionizing radiation and large volumes of
iodinated contrast material (21,30,31).
Previous studies have shown that
gadobenate dimeglumine (MultiHance;
Bracco Imaging, Milan, Italy) is an effec-
tive contrast agent for use in CE MR
angiography of the renal arteries (32–
34). Although a dose of 0.1 mmol per
kilogram of body weight gadobenate
dimeglumine is equivalent to a dose of
0.2 mmol/kg gadopentetate dimeglu-
mine in terms of renal artery contrast
enhancement and diagnostic image
quality (32,34), no data have yet been
reported concerning overall diagnostic
accuracy of CE MR angiography with
0.1 mmol/kg gadobenate dimeglumine
for the detection of hemodynamically
significant steno-occlusive disease of the
renal arteries. Thus, the purpose of our
study was to prospectively determine
the diagnostic performance and safety
of CE MR angiography with 0.1
mmol/kg gadobenate dimeglumine for
depiction of significant steno-occlusive
disease (51% stenosis) of the renal
arteries, with digital subtraction angiog-
raphy (DSA) as the reference standard.
Materials and Methods
This was a phase 3, multicenter, open-
label trial conducted at 35 investiga-
tional centers in North and South Amer-
ica, as well as Europe. The study was
reviewed and approved by the local in-
stitutional review board or ethics com-
mittee of each of the participating cen-
ters in accordance with the Good Clini-
cal Practice guideline (Committee for
Proprietary Medical Products, Interna-
tional Conference of Harmonization,
direction 135/95, London, July 2002),
which is available at www.emea.europa
.eu/pdfs/human/ich/013595en.pdf, and
was performed in adherence to the Dec-
laration of Helsinki (Helsinki, Finland,
1964) and subsequent amendments.
Centers in the United States of America
were fully compliant with the Health In-
surance Portability and Accountability
Act. All evaluated patients provided
written informed consent before enroll-
ment in the study. Each investigator was
supported by an operating grant from
Bracco Diagnostics (Princeton, NJ) and
was supplied with the investigational
contrast agent solely for the purpose of
the study. One author (D.A.B.) is a con-
sultant to Bracco Diagnostics; another
(J.H.M.) is on the speaker bureau and
has received research funding from
Bracco Diagnostics. The authors who
are employees of Bracco Imaging (M.A.K.)
and Bracco Diagnostics (G.P.) had no
control over patient enrollment or data
acquisition. All authors who were not
Bracco employees had full control of all
data and information included in the
present article.
Study Group
All patients were enrolled between April
2002 and January 2005. For inclusion,
patients had to be at least 18 years old
with a diagnostic determination positive
for RAS that was based on Doppler US,
CT angiographic, or renal scintigraphic
findings or a moderate (5%–15%) clin-
ical index of suspicion for any renovas-
cular form of hypertension (35). The
clinical index of suspicion included at
least one of the following criteria: se-
vere hypertension (diastolic blood pres-
sure, 100 mm Hg), hypertension un-
responsive to standard therapy (hyper-
tension resistant to treatment with at
least three medications of different
classes, including diuretics), abrupt on-
set of sustained moderate to severe hy-
pertension at younger than 35 years of
age, and progressive renal insufficiency
(serum creatinine level, 2 mg/dL
[176 mol/L]).
Patients were ineligible for inclusion
if they had received a kidney transplant
or had surgically implanted appara-
tuses, such as metallic vascular stents or
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Abbreviations:
CE  contrast enhanced
CI  confidence interval
DSA  digital subtraction angiography
MIP  maximum intensity projection
NLR  negative likelihood ratio
NPV  negative predictive value
PLR  positive likelihood ratio
PPV  positive predictive value
RAS  renal artery stenosis
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Advances in Knowledge
 MR angiography enhanced with
gadobenate dimeglumine at a sin-
gle dose of 0.1 mmol per kilogram
of body weight provides good sen-
sitivity (60%–84%), specificity
(89%–95%), and diagnostic accu-
racy (80%–87%) for the detec-
tion of clinically significant renal
artery stenosis (RAS).
 The use of gadobenate dimeglu-
mine at a single dose of 0.1
mmol/kg in patients who are sus-
pected of having renovascular dis-
ease is safe on the basis of clinical
examination findings, 24-hour
monitoring for adverse events,
and results of blood tests and
urinalysis.
Implication for Patient Care
 MR angiography with gadobenate
dimeglumine at a single dose of
0.1 mmol/kg can be used for the
depiction of RAS in patients who
are clinically suspected of having
renovascular hypertension.
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pacemakers. Patients with a known his-
tory of hypersensitivity to metals or to
gadolinium-based and/or iodinated con-
trast media also were ineligible. Pa-
tients who received any other investiga-
tional contrast agent within 60 days
prior to the study or any other contrast
agent within 24 hours prior to or after
gadobenate dimeglumine administration
also were ineligible. Pregnant or lactat-
ing women or patients with class III or
IV congestive heart failure according to
the New York Heart Association classi-
fication also were ineligible for inclusion
(36). Patients were eligible for inclusion
regardless of their serum creatinine
level. Similarly, patients who were re-
ceiving ongoing dialysis were not con-
sidered ineligible for inclusion.
All patients were required to pro-
vide written informed consent before
enrollment in the study and to undergo
a DSA examination before or within 1
month after gadobenate dimeglumine
administration. No patient was permit-
ted any other surgical procedure within
24 hours after gadobenate dimeglumine
administration.
A total of 304 patients met the in-
clusion criteria and were enrolled in the
study. Of these 304 patients, 293 (154
men, 139 women; mean age, 61.0
years  14.5 [standard deviation];
range, 18–93 years) received gado-
benate dimeglumine at a dose of 0.1
mmol/kg and were evaluated for safety
(Fig 1). The remaining 11 discontinued
participation prior to contrast agent ad-
ministration for the following reasons:
claustrophobia (n  3), study cancella-
tion by the interventionalist on the day
of the study (n  1), panic (n  1),
severe coughing (n  1), withdrawal of
consent before the trial (n  1), techni-
cal problems with MR imager (n  1),
difficulty in placement of the intrave-
nous catheter (n  1), failure to meet
inclusion criteria after signing the pa-
tient consent form (n  1), and absence
of medical history in regard to prior
cardiac intervention (n  1).
Of 293 enrolled patients, approxi-
mately one-half (n  136, 46.4%) were
65 years or older, whereas 125 (42.7%)
were 41–64 years old and 32 (10.9%)
were 18–40 years old. The 293 evalu-
ated patients included 241 (82.2%) with
a moderate clinical index of suspicion
for renovascular hypertension and 33
(11.3%) who had progressive renal in-
sufficiency. The remaining 19 (6.5%)
patients had no current symptoms but
were suspected of having RAS on the
basis of findings from previous imaging
studies. Of the 293 patients in whom
safety was evaluated, 25 patients were
excluded from evaluation of diagnostic
performance because no DSA examina-
tion was performed. Thus, in 293 pa-
tients, safety was evaluated, and in 268
patients who underwent DSA, diagnos-
tic performance was evaluated.
MR Angiography
All patients underwent MR angiogra-
phy with 1.5-T commercially available
MR imagers equipped with a gradient
strength of 20 mT/m or greater. Sev-
eral MR imagers were used for the
study: Four were from one manufac-
turer (Symphony [n  70, 23.9%], So-
nata [n  48, 16.4%], Vision [n  35,
11.9%], Avanto [n  4, 1.4%]; Sie-
mens Medical Systems, Erlangen, Ger-
many). Two were from another man-
ufacturer (Intera [n  63, 21.5%] and
Marconi Infinion [n  11, 3.8%]; Phil-
ips Medical Systems, Best, the Neth-
erlands). Two others were from a
third manufacturer (Genesis Signa
[n  49, 16.7%] and Excite [n  13,
4.4%]; GE Medical Systems, Milwau-
kee, Wis).
MR angiography was performed by
using a three-dimensional spoiled gradi-
ent-echo sequence before and immedi-
ately after administration of gadobenate
dimeglumine. The large number of in-
vestigating centers involved in the study
and the wide variety of imaging systems
in use resulted in necessarily different
sequence parameters between centers.
Nevertheless, each sequence at each
center was selected to meet minimal re-
quirements for image acquisition and
interpretability. The sequence parame-
ters for the image acquisition (before
interpolation, if any) varied as follows:
For coronal orientation, parameters in-
cluded repetition time msec/echo time
msec, 2.84–6.5/0.97–2.5; flip angle,
20°–45°; number of signals acquired,
0.5–1; section thickness, 1–2 mm; ma-
trix, 256–512  192–320; pixel size,
1.41–0.55  1.41–1.10 mm; and over-
all acquisition time, 25 seconds or less.
The vascular field of view was tailored
for each patient to include the kidneys,
the abdominal aorta, the renal arteries,
and an area from 2 cm above the origin
of the celiac trunk to the common iliac
artery bifurcations, including the bifur-
cation of the celiac axis and the first 2
cm of the superior mesenteric artery.
The overall image acquisition time
ranged between 12 and 25 seconds, de-
pending on the MR imager, sequence
parameters, and field of view used.
The CE MR angiographic sequence
was performed after administration of
Figure 1
Figure 1: Flow diagram depicts
patient enrollment, patient discon-
tinuation, and diagnostic exami-
nations performed.MRAMR
angiography.
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gadobenate dimeglumine at a dose of
0.1 mmol/kg. Contrast agent adminis-
tration was performed by means of a
power injector at a rate of 2 mL/sec,
followed by a 20-mL saline flush at the
same rate. Timing for the CE MR an-
giographic sequence was achieved by
means of a bolus-timing acquisition in
162 patients or through use of an au-
tomatic or MR fluoroscopic bolus de-
tection technique (SmartPrep, GE
Medical Systems; BolusTrak, Philips
Medical Systems; CareBolus, Sie-
mens Medical Systems) in 131 pa-
tients. The test bolus timing approach
involved acquisition of 45–60 dynamic
single-section T1-weighted fast gradi-
ent-echo images of the abdominal
aorta at a frequency of one image per
second after administration of a pre-
liminary 2-mL bolus of gadobenate
dimeglumine.
DSA: Reference Standard
DSA was performed by experienced
(range, 6–22 years) investigators with
injection of 20–40 mL of iodinated
contrast medium at a rate of 10–20
mL/sec through a pigtail or straight
4–5-F aortic-flush catheter inserted
via a femoral artery puncture by using
the Seldinger technique. An antero-
posterior projection, as well as right
anterior oblique and left anterior
oblique projections at angles of 15°–
30°, of the renal arteries was obtained
as appropriate according to each cen-
ter’s standard operating procedure.
Selective cannulation and opacifica-
tion of the renal arteries was per-
formed if deemed necessary on the
basis of the judgment of the local in-
vestigator. DSA examinations were
performed with a matrix of 1024 
1024 at a frame rate of at least 2
frames per second. Most (191
[71.5%] of 268) of the DSA examina-
tions were performed within 30 days
after the MR angiographic examination,
whereas the remaining (77 [28.7%] of
268) examinations were performed
within 60 days before MR angiography.
Most (260 [97%] of 268) DSA examina-
tions were performed by using iodin-
ated contrast media with iodine concen-
trations of more than 200 mg of iodine
per milliliter (200–300 mg of iodine per
milliliter in 38% of the patients; 300
mg of iodine per milliliter in 62% of the
patients).
Image Evaluation
Images were evaluated by on-site inves-
tigators at each of the 35 investigational
centers (each investigator had 10–15
years of experience with MR angiogra-
phy) and by four off-site independent
experienced board-certified radiologists
(R.C., M.N.W., and T.R.M. [with ap-
proximately 20, 15, and 15 years of ex-
perience in vascular imaging, respec-
tively] for MR angiographic images and
C.B. [with approximately 12 years of
experience] for DSA images) who were
not affiliated with any of the study sites
and were fully blinded to all patient in-
formation and to the results of other
diagnostic procedures. Each of the
three off-site blinded readers of CE MR
angiographic images evaluated all MR
angiographic image sets from each of
the 268 evaluable patients.
Off-site evaluation of digital MR an-
giographic and DSA images was per-
formed at an independent core imaging
laboratory equipped with two separate
software-based (Windows; Microsoft,
Redmond, Wash) workstations (Aquar-
ius Net Viewer; TeraRecon, San Mateo,
Calif) for evaluation of images (two
monitors) and for recording of assess-
ment findings by using an electronic
case report form system. All CE MR
angiographic images were combined
into a single randomization pool, and
each image set for each patient was re-
viewed separately, one at a time, and in
a randomized order. For each reader,
both source images and volumetric
maximum intensity projection (MIP) re-
constructions were displayed on the two
monitors set up for image evaluation.
All routine image review tools (window
width and window level, zoom, pan,
etc) were available to the readers.
The three off-site readers of MR
angiographic images performed their
evaluations independently in a fully
blinded fashion. For evaluation, the
renal arterial anatomy was divided
into standard segments comprising
the left and right main renal arteries
(from the ostium to the subdivision in
the dorsal and ventral segmental
branches) and the left and right seg-
mental branches of the renal arteries
(second- and third-order segmental
branches). Accessory arteries were
assessed whenever present.
Initial off-site evaluation was per-
formed to determine the technical ade-
quacy (quality of visualization) of the CE
MR angiographic image sets. If any seg-
ment was not entirely in the field of view
or was considered technically inade-
quate for any reason, no further assess-
ment was performed for that segment.
Assessment of diagnostic performance
was then performed for all technically
adequate main renal artery segments by
using a three-point scale in which a
score of 1 indicated stenosis of 50% or
less (blood vessel with no clinically sig-
nificant disease); a score of 2, stenosis
of 51%–99% (blood vessel with clini-
cally significant disease); and a score of
3, occlusion (blood vessel with 100%
blockage of the vessel lumen). All as-
sessments were made visually on the
basis of the experience of the blinded
readers and as routinely performed in
clinical practice. Electronic calipers were
available, if necessary, for quantifica-
tion of borderline stenoses (ie, stenoses
of approximately 50% vessel lumen nar-
rowing) but were not systematically
used. In all cases, determination of the
degree of stenosis was made by compar-
ing the part of the blood vessel in ques-
tion with areas of normal renal artery
that were well away from areas below
the stenotic dilatation.
Additional assessments were per-
formed to determine possible involve-
ment of the ostium (possible answers
included yes, no, and ostium not visual-
ized) for whichever main renal arteries
were determined to harbor significant
stenosis or occlusion, to determine the
presence of accessory renal arteries
originating either above or below the
origin of the main renal arteries, and to
ascertain whether detected disease was
nodular in appearance (ie, fibromuscu-
lar dysplasia).
Off-site evaluation of DSA images
was performed by using similar assess-
ment methods and criteria. For this
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evaluation, DSA images were combined
in a second pool, different from the MR
angiographic pool.
On-site evaluation of MR angio-
graphic images was performed by using
criteria similar to those of the off-site
evaluation. Evaluation was performed
by an experienced radiologist at each
investigational site who was blinded to
the results of the DSA examination. CE
MR angiographic image sets were evalu-
ated separately in terms of quality of
visualization of arterial segments (tech-
nical adequacy), the presence and num-
ber of accessory renal arteries and the
quality of their visualization, and the
presence and grading of stenosis. With
the same assessment criteria, on-site
evaluation of DSA images was per-
formed by a second experienced investi-
gator who was fully blinded to the re-
sults of the on-site MR angiographic
evaluations.
Safety Evaluations
Physical examination was performed
within 24 hours prior to gadobenate
dimeglumine administration and at 24
hours after administration. Measure-
ment of vital signs (blood pressure and
heart rate) was performed within 24
hours prior to administration; prior to
entering the magnet; and at 30 minutes,
1 hour, and 24 hours after gadobenate
dimeglumine administration. Recording
of electrocardiograms was similarly per-
formed before the patient entered the
bore of the magnet and at 1 hour and 24
hours after gadobenate dimeglumine
administration.
In addition, blood and urine samples
were collected within 24 hours prior to
gadobenate dimeglumine administration
and at 24 hours after administration.
Laboratory evaluation of collected sam-
ples consisted of hematologic tests (he-
matocrit level, hemoglobin level, as well
as red blood cell, white blood cell, and
platelet counts), blood chemistry analy-
sis (serum glucose, serum creatinine,
total serum bilirubin, total serum pro-
tein, serum albumin, serum aspartate
aminotransferase, serum alanine ami-
notransferase, serum alkaline phospha-
tase, serum -glutamyl transpeptidase,
plasma sodium, plasma potassium, and
plasma chloride levels), and urinalysis
(amount of protein and glucose, pres-
ence of ketones and blood, and pH test).
Finally, the safety of gadobenate
dimeglumine was assessed by on-site in-
vestigators in terms of the incidence of
clinical adverse events from the time of
signed informed consent until 24 hours
after gadobenate dimeglumine adminis-
tration. Adverse events were classified
as either serious (ie, death, life threat-
ening, requiring or prolonging hospital-
ization) or not serious (rated as mild
[not resulting in disability or incapacity
and resolved without treatment], mod-
erate [not resulting in disability or inca-
pacity but required treatment], or se-
vere [resulting in temporary and/or
mild disability or incapacity and re-
quired treatment]). The relationship of
each adverse event to the study contrast
agent was classified as probably related,
possibly related, not related, or un-
known. All decisions in regard to the
severity of adverse events and their pos-
sible relationship to the study contrast
agent were made by the investigating
radiologist at each center.
Statistical Analysis
The primary objective was to determine
the diagnostic performance of CE MR
angiography with 0.1 mmol/kg gado-
benate dimeglumine for detection of sig-
nificant steno-occlusive disease (defined
as stenosis of51% or occlusion) of the
main renal arteries, with DSA as the
reference standard. Separate determi-
nations were made of the sensitivity,
specificity, and accuracy of CE MR an-
giography, including 95% confidence in-
tervals (CIs) derived from generalized
estimating equation analysis, as well as
of the positive predictive value (PPV),
negative predictive value (NPV), posi-
tive likelihood ratio (PLR), and negative
likelihood ratio (NLR) for the detection
of significant disease. Data from each of
the three off-site readers of MR angio-
graphic images and from the on-site in-
vestigators were analyzed and pre-
sented separately.
Sensitivity for detection of significant
steno-occlusive disease at the segment
level was defined as the number of cor-
rectly identified significantly diseased
(51% stenosis) main renal artery seg-
ments evaluated on CE MR angiographic
images divided by the total number of
significantly diseased (51% stenosis)
segments evaluated on DSA images.
Specificity was defined as the number of
correctly identified main renal artery seg-
ments that were not diseased or not sig-
nificantly diseased (50% stenosis) eval-
uated on CE MR angiographic images di-
vided by the total number of segments
that were not diseased or not significantly
diseased (50% stenosis) evaluated on
DSA images. Accuracy was defined as the
number of correctly identified main renal
artery segments (either diseased or non-
diseased) evaluated on CE MR angio-
graphic images divided by the total num-
ber of segments evaluated on DSA
images. All uninterpretable CE MR an-
giographic images were considered in-
accurate for all determinations of diag-
nostic performance. If a segment was
not adequately visualized or the image
was technically inadequate, this seg-
ment was considered false-positive for
steno-occlusive disease if the corre-
sponding DSA image revealed a stenosis
of 50% or less; however, this segment
was considered false-negative for steno-
occlusive disease if the corresponding
DSA image revealed a stenosis of 51%
or more or occlusion.
Determination of the diagnostic per-
formance of CE MR angiography, in-
cluding 95% CIs, also was performed at
the patient level. For this evaluation, a
patient with true-positive findings was
one in whom at least one of the main
renal arteries was true-positive for
steno-occlusive disease at CE MR an-
giography, a patient with false-positive
findings was one in whom one of the
main renal arteries was false-positive
for steno-occlusive disease at CE MR
angiography, a patient with false-nega-
tive findings was one in whom one of the
main renal arteries was false-negative
for steno-occlusive disease at CE MR
angiography, and a patient with true-
negative findings was one in whom both
main renal arteries were true-negative
for steno-occlusive disease at CE MR
angiography.
Interreader agreement at the seg-
ment level was assessed as the percent-
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age of concordance among the three
readers of MR angiographic images by
means of the generalized  coefficient.
Interreader agreement was classified as
very good for  values great than 0.80,
good for  values of 0.61–0.80, moder-
ate for  values of 0.41–0.60, fair for 
values of 0.21–0.40, or poor for  val-
ues of 0.20 or less.
The technical failure rate of the CE
MR angiographic sequence was defined
as the total number of technically inade-
quate segments divided by the total
number of segments included in the field
of view. A comparison with the techni-
cal failure rate of DSA was performed
by using the Fisher exact test.
Statistical analysis of data was per-
formed by using a statistical software
package (SAS, version 8.2; SAS Insti-
tute, Cary, NC).
Results
Technical Adequacy and Quality of
Segment Visualization
The technical adequacy rate of CE MR
angiography for evaluation of the renal
arteries in all 293 patients who received
gadobenate dimeglumine ranged between
1.9% and 2.8% for the off-site blinded
readers, whereas a slightly higher value of
4.5% was obtained for the on-site inves-
tigators (Table E1[radiology.rsnajnls
.org/cgi/content/full/2471070711/DC1]).
Overall, the technical failure rate of CE
MR angiography for the renal arteries
was low in absolute terms and was com-
parable to the technical failure rate of
DSA (0.8%; four segments considered
technically inadequate by the reader of
DSA images).
Diagnostic Performance
A total of 268 patients underwent both
MR angiography and DSA examinations
and were included in evaluations of di-
agnostic performance. With DSA, 178
(66.4%) of 268 patients were deter-
mined to have significant steno-occlu-
sive disease (51% stenosis) of one or
more renal artery segments (including
main and accessory renal arteries).
These 178 patients comprised 113
(42.2%) with clinically significant dis-
ease in one segment and 65 (24.2%)
with significant disease in more than
one segment.
DSA images of eight of the 536 main
renal artery segments theoretically avail-
able for evaluation (two per patient) were
either technically inadequate or unavail-
able. Therefore, determination of the di-
agnostic performance of CE MR angiog-
raphy was performed for a total of 528
main renal artery segments. A total of
200 (37.9%) of 528main renal artery seg-
ments evaluated at DSAwere determined
to have either significant stenosis of 51%
or greater (n  187) or occlusion (n 
13). On CE MR angiographic images, off-
site readers 1, 2, and 3 reported signifi-
cant disease (51% stenosis or occlu-
sion) for 26.2% (135 of 516), 30.8% (160
of 519), and 33.5% (174 of 519) of the
main renal artery segments evaluated at
DSA, respectively. Similar findings were
reported by the on-site investigators
(35.9% [188 of 523] of evaluated main
renal arteries). Renal artery occlusion
was noted for 1.6% (eight of 516), 2.5%
(13 of 519), 1.9% (10 of 519), and 1.1%
(six of 523) main renal artery segments
by off-site readers 1, 2, and 3 and the
on-site investigators, respectively.
With regard to the diagnostic perfor-
mance of CE MR angiography for the de-
tection of significant steno-occlusive dis-
ease of the main renal arteries (Table 1)
for the segment-based analysis, sensitiv-
ity values of 60.1%, 74.5%, and 73.9%
were determined by off-site readers 1, 2,
and 3, respectively, whereas a slightly
higher value of 84.1% was determined by
the on-site investigators. Conversely,
specificity values of 93.1%, 94.7%, and
89.4% were obtained by off-site readers
1, 2, and 3, respectively, whereas a
slightly lower value of 87.7% was ob-
tained by the on-site investigators.
The values for diagnostic accuracy were
similar for both off-site readers
(80.4%–86.9%) and on-site investiga-
tors (86.4%). Comparable values for
PPV, NPV, PLR, and NLR were ob-
tained for both off-site readers and on-
site investigators (Table 2).
The agreement among the three off-
site readers for detection of clinically
significant steno-occlusive disease was
Table 1
Sensitivity, Specificity, and Accuracy and 95% CIs of CE MR Angiography for Segment-Level Detection of Significant Steno-occlusive
Disease of the Main Renal Arteries Relative to DSA
Off-site Reader 1 Off-site Reader 2 Off-site Reader 3 On-site Investigators
Parameter Value (%) 95% CI Value (%) 95% CI Value (%) 95% CI Value (%) 95% CI
Sensitivity* 60.1 (119/198) 52.8, 66.7 74.5 (149/200) 68.1, 80.1 73.9 (147/199) 67.6, 79.5 84.1 (153/182) 77.6, 88.8
Specificity† 93.1 (296/318) 89.1, 95.4 94.7 (302/319) 90.8, 96.5 89.4 (286/320) 85.0, 92.2 87.7 (299/341) 83.1, 90.7
Accuracy‡ 80.4 (415/516) 76.6, 83.7 86.9 (451/519) 83.5, 89.6 83.4 (433/519) 79.8, 86.5 86.4 (452/523) 82.6, 89.1
Note.—Numbers in parentheses were used to calculate the percentages. Segments considered outside the field of view on CE MR angiographic images were excluded from assessment. The 95%
CIs were derived from a generalized estimating equation, with patient cluster effect taken into account.
* Sensitivity is the number of correctly identified diseased (51% stenosis) main renal artery segments on CE MR angiographic images divided by the total number of significantly diseased segments
on DSA images.
† Specificity is the number of correctly identified nondiseased or not significantly diseased (50% stenosis) main renal artery segments on CE MR angiographic images divided by the total number
of nondiseased or not significantly diseased segments on DSA images.
‡ Accuracy is the number of correctly identified main renal artery segments (either diseased or nondiseased) on CE MR angiographic images divided by the total number of segments evaluated on
DSA images.
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good (79.9% agreement;   0.69).
Agreement of the CE MR angiographic
findings with the DSA results was noted
for 75%–77% of all cases (all readers)
in which the location of a significant ste-
nosis on DSA images was judged as os-
tial (Fig 2). Good correlation between
CE MR angiography and DSA was also
noted for cases of nonsignificant steno-
sis of 50% or less (Fig 3). Although only
seven enrolled patients were diagnosed
with fibromuscular dysplasia, a nodular
appearance typical of this disease was
well observed on CE MR angiographic
images (Fig 4).
In regard to the diagnostic perfor-
mance of CE MR angiography at the
patient level (Table 3), overall values for
sensitivity, specificity, accuracy, PPV,
and NPV were similar to those deter-
mined in the segment-based analysis.
Detection and Evaluation of Accessory
Renal Arteries
The blinded reader of DSA images re-
ported a total of 113 accessory renal ar-
teries. Blinded readers 1, 2, and 3 of CE
MR angiographic images detected 66.4%,
67.3%, and 76.1%, respectively, of these
accessory renal arteries (Table E2
[radiology.rsnajnls.org/cgi/content/full
/2471070711/DC1]) (Fig 5). In 10 cases
(three each for readers 1 and 2 and four
for reader 3), accessory renal arteries
were detected on CE MR angiographic
images but not on DSA images.
Safety
A total of 39 nonserious adverse events
reported by 27 (9.2%) of 293 patients
were considered probably related or
possibly related to the administration of
gadobenate dimeglumine or the rela-
tionship was unknown. These events
were mild in intensity in 26 (8.9%) pa-
tients and moderate in intensity in one
(0.3%) patient. There was no trend in
regard to the distribution of adverse
events among the evaluated patients,
and no consistent trends in vital signs,
electrocardiogram, or laboratory pa-
rameters were observed. Overall, eight
events in eight of these 27 patients
(29.6%; 2.7% [eight of 293] overall)
were considered local in nature (heat
sensation or injection site pain, bruis-
ing, or swelling). A total of five gastroin-
testinal disorders (diarrhea [n  1],
nausea [n  3], tongue edema [n  1])
were reported as study contrast agent–
related adverse events by four patients,
whereas 11 minor and clinically unim-
portant alterations of laboratory param-
eters in eight patients were also re-
ported as adverse events. The remain-
ing nonserious adverse events were
abnormal taste sensation (n  4), fa-
tigue (n  3), headache (n  3), hypo-
tension (n  2), chest pain (n  1),
burning sensation (n  1), and hema-
toma (n 1). No serious adverse events
potentially related to the administration
of gadobenate dimeglumine were re-
ported. No additional potentially study
contrast agent–related adverse events
were reported following the specified
24-hour monitoring period.
Discussion
Our study results confirm previous find-
ings (32–34) in demonstrating that CE
MR angiography with gadobenate dime-
glumine is safe for diagnostic evaluation
of the renal vasculature in patients with
suspected renovascular disease. More-
over, our study results also confirm that
CE MR angiography with gadobenate
dimeglumine at a single dose of 0.1
mmol/kg provides good sensitivity and
high specificity and diagnostic accuracy
for the detection of clinically significant
steno-occlusive disease (51% steno-
sis) of the renal arteries.
Researchers in previous studies with
other gadolinium-based contrast agents
have generally used doses of between 0.1
and 0.3 mmol/kg, with investigators in
several studies advocating doses of 0.2
mmol/kg and higher (1,2,10,13–15,
20,21,26,29,31). The possibility to use
a lower dose of gadobenate dimeglu-
mine to achieve signal intensity en-
hancement similar to that achieved
with a double dose of a conventional
gadolinium-based contrast agent
(32,34) is ascribable to its increased
r1 relaxivity and the subsequent
shorter blood T1 for any given dose.
This effect derives from weak and
transient interactions of the gadolin-
ium benzyloxypropionictetraacetate
complex of gadobenate dimeglumine
with serum albumin (37–39), interac-
tions that reduce the tumbling rate of
the gadolinium benzyloxypropionictet-
raacetate complex in blood that re-
sults in increased r1 and r2 relaxivities
of this contrast agent relative to those
of other available contrast agents that
do not interact with serum pro-
teins (40).
Findings in studies in vitro (41),
which have been supported by observa-
tions in the clinical setting (33,42), sug-
gest that the r1 relaxivity of gadobenate
dimeglumine is concentration dependent
with higher relaxivity values and, hence,
greater signal intensity enhancement at
lower concentrations. Given the current
widespread concern among the radiology
community concerning the use of double
and triple doses of gadolinium-based con-
trast agents, particularly in patients with
renal insufficiency in regard to the risk of
nephrogenic systemic fibrosis (43,44),
Table 2
PPV, NPV, and Likelihood Ratios for CE MR Angiography Relative to DSA
Statistic Off-site Reader 1 Off-site Reader 2 Off-site Reader 3 On-site Investigators
PPV (%)* 84.4 (119/141) 89.8 (149/166) 81.2 (147/181) 78.5 (153/195)
NPV (%)† 78.9 (296/375) 85.6 (302/353) 84.6 (286/338) 91.2 (299/328)
PLR‡ 8.7 14.0 7.0 6.8
NLR§ 0.4 0.3 0.3 0.2
* PPV is the number of correctly identified diseased (51% stenosis) segments divided by the total number of segments
considered positive for steno-occlusive disease. Numbers in parentheses were used to calculate the percentages.
† NPV is the number of correctly identified nondiseased (50% stenosis) segments divided by the total number of segments
considered negative for steno-occlusive disease. Numbers in parentheses were used to calculate the percentages.
‡ PLR is sensitivity divided by the remainder of specificity subtracted from one.
§ NLR is the remainder of sensitivity subtracted from one divided by specificity.
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our results with just a single 0.1 mmol/kg
dose of gadobenate dimeglumine are of
interest.
Although the specificity of CE MR an-
giography was approximately 90% for all
readers in the segment-based analysis,
the sensitivity values were approximately
74% for two of the off-site blinded read-
ers and slightly lower (60.1%) for off-site
blinded reader 1. Conversely, the sensi-
tivity determined by the on-site investiga-
tors was 84.1% in an image reading situ-
ation far more akin to that of the routine
clinical environment than that with which
the off-site blinded reading was con-
ducted. To date, researchers in only one
prospective multicenter study conducted
in patients who were suspected of having
RAS have combined independent blinded
reading with a sample size larger than
ours (45). In that study, Vasbinder et al
(45) compared CE MR angiography with
DSA in patients who were suspected of
having RAS and found sensitivity and
specificity values of just 62% and 84%,
respectively. Although the precise dose of
contrast agent was not reported in their
study, the contrast agent volume admin-
istered tomost of the patients was 30mL,
which corresponds to doses between
0.15 and 0.22 mmol/kg for patients who
weigh 70–100 kg.
The overall accuracy for the detection
of significant renal artery stenosis ex-
ceeded 80% for all readers in the seg-
ment-based analysis. This compares ex-
tremely favorably with values reported
for gadodiamide (Omniscan; GE Health-
care, Oslo, Norway) and gadopentetate
dimeglumine (Magnevist; Bayer Schering
Pharma, Berlin, Germany) in a study to
evaluate 0.1 mmol/kg doses of these
agents for detection of significant abdom-
inal and iliac stenosis (46). Our values for
sensitivity, specificity, and accuracy also
compare favorably with corresponding
values determined in phase 3 clinical tri-
als to evaluate another gadolinium-based
contrast agent (gadofosveset, Vasovist;
Bayer Schering Pharma) for CE MR an-
giography of renal (47) and aortoiliac oc-
clusive disease (48,49). Although the vas-
cular territory under consideration was
different for the studies with gadofosve-
set, the three readers in each case would
have been subjected to similarly rigorous
blinding and assessment conditions to
those experienced in our study.
Overall, our results for diagnostic
performance are slightly lower than the
findings in a previous meta-analysis (50)
in which sensitivity was reported to vary
between 88% and 100% and specificity
between 71% and 100%. Reasons for
these lower results include methodologi-
cal differences and the fact that all blinded
readers in our study were not affiliated
with the enrollment centers and were un-
aware of the patient eligibility criteria, as
well as all clinical and radiologic informa-
tion. Although blinded and independent
reading eliminates much of the potential
for bias, it imposes a condition that does
not exist in clinical routine. This im-
Figure 2
Figure 2: Images in 75-year-old man with history of left nephrectomy and high blood pressure with pro-
gressive renal failure. (a)Subvolume MIP coronal projection of CE MR angiographic acquisition (4.6/1.8)
reveals severe ostial stenosis (arrow) of right renal artery. (b)Curved transverse multiplanar reconstruction
confirms severity of stenosis in ostial portion of renal artery. (c)Aortographic image shows ostial stenosis
(arrow) estimated at more than 90%. (d)Selective angiographic image of right renal artery acquired before
balloon angioplasty confirms stenosis of more than 90%.
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posed condition may hamper assess-
ment of the clinical significance of a bor-
derline stenosis, thereby leading to
lower overall agreement with DSA find-
ings. Nevertheless, the good reproduc-
ibility of the blinded reading results in
this study, together with the acceptable
magnitude of the results despite limita-
tions imposed by the blinded reading
method, indicates the high validity and
reliability of this approach.
A further point that may contribute to
the diagnostic performance results ob-
tained is that determinations of diagnostic
accuracy reported in the relevant litera-
ture typically do not include data from
technically inadequate images (51). This
omission potentially increases the sensitiv-
ity and specificity of CEMR angiography
in those studies. In our study, all unin-
terpretable images of blood vessels
were considered inaccurate and were
included in the calculations for sensitiv-
ity, specificity, and overall accuracy. Al-
though the elimination of evaluation
bias in our study certainly affected the
overall diagnostic performance values,
the results should nevertheless be con-
sidered a more realistic reflection of
clinical practice and should be borne in
mind when considering apparent inter-
study differences in diagnostic perfor-
mance results.
When one assesses the diagnostic
performance values obtained in this
study, one must also consider that,
whereas most studies reported in the lit-
erature have been performed in relatively
small numbers of patients—thereby pre-
cluding the drawing of robust conclu-
sions concerning study findings—our
data derive from 35 different centers
with widely varying equipment and,
consequently, slightly different imaging
protocols. Finally, it should also be
borne in mind that DSA, as any refer-
ence standard, although very accurate,
is not perfect; and discrepancies be-
tween MR angiographic and DSA find-
ings can be caused by errors in interpre-
tation of findings with either modality.
Limitations of conventional DSA as a
reference standard technique have re-
cently been highlighted by Anzalone et
al (52) for CE MR angiography of the
carotid arteries. Notwithstanding the
artificial environment with which off-
site image evaluation was performed,
the diagnostic performance determined
by the three blinded readers can be con-
sidered very satisfactory for assess-
ments performed at both the segment
and the patient level.
Of particular interest in our study is
the strong interreader agreement dem-
onstrated for the diagnosis of clinically
significant RAS. Specifically, all three
blinded readers of MR angiographic im-
ages agreed in almost 80% of segment
evaluations, yielding a  value of 0.69.
Figure 3
Figure 3: Images in 65-year-old woman with coronary artery disease, diabetes, and hypertension. (a)MIP
coronal projection of CE MR angiographic acquisition (3.29/1.17) reveals moderate nonsignificant stenosis
(arrow) of right renal artery. (b)Angiographic image of abdominal aorta and selective opacification of right
renal artery confirms moderate stenosis (arrow) of right renal artery and demonstrates good correlation with
CE MR angiographic findings.
Figure 4
Figure 4: Images in 56-year-old man with severe hypertension, cardiac transplantation, and renal insuffi-
ciency. (a)MIP coronal projection of CE MR angiographic acquisition (5.12/1.5) reveals dilatation (arrow)
and stenosis of right renal artery indicative of fibromuscular dysplasia. (b)Corresponding DSA image simi-
larly shows renal artery dilatation (arrow) and demonstrates good correlation with CE MR angiographic study.
Atheromatous infiltration of right renal artery and intrarenal branches suggests a lesion combining fibromus-
cular dysplasia and atherosclerosis.
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On the basis of the guidelines presented
by Landis and Koch (53) to describe the
clinical value of degree of concordance,
this value indicates that gadobenate dime-
glumine–enhanced MR angiography is a
diagnostic test with “substantial” repro-
ducibility. Notably, the agreement ob-
tained in our study is considerably bet-
ter than the moderate three-reader
agreement (  0.40–0.51) obtained by
Vasbinder et al (45) and better also
than the mean two-reader agreement
(  0.49) obtained by Vo¨lk et al (27) in
a study to assess the value of time-re-
solved MR angiography for the detec-
tion of RAS.
Confirmation of the value of CE MR
angiography for diagnostic evaluation of
the renal arteries comes from the predic-
tive values determined for the three
blinded readers. The PPV determinations
in this study indicate that a vascular seg-
ment with positive findings at CE MR an-
giography with gadobenate dimeglumine
is up to 90% likely to have significant
steno-occlusive disease. These results are
highly encouraging, especially consider-
ing the artificial environment in which
they were obtained. The NPV results
(78.9%–85.6%) indicated that the risk of
overlooking steno-occlusive disease at CE
MR angiography with gadobenate dime-
glumine is low. Therefore, normal find-
ings at CE MR angiography with gado-
benate dimeglumine should obviate fur-
ther potentially hazardous conventional
angiographic or surgical procedures and,
thus, eliminate possible risks (contrast
agent nephrotoxicity, exposure to ioniz-
ing radiation, and catheter-induced athe-
roembolism) associated with these proce-
dures.
In contrast to the predictive values
and values for sensitivity and specificity,
the values for PLR and NLR are not
affected by the prevalence of disease
(54). Thus, determination of these val-
ues offers an approach to assessing di-
agnostic performance that is unaffected
by the condition being evaluated in the
population. Whereas the PLR indicates
the effect of a positive examination find-
ing on the probability that the condition
in question exists, the NLR addresses
the effect of a negative examination
finding on the probability that the condi-
tion in question is present. The likeli-
hood values therefore provide quantifi-
cation of the effect of MR angiographic
results on diagnostic thinking (ie, the
effect of the MR angiographic test result
on the a priori probability of the pres-
ence of clinically significant steno-occlu-
sive disease versus the a posteriori
probability of the presence of such dis-
ease) (55). In this study, a PLR value of
seven or higher for each blinded reader
suggests that a positive finding on CE
MR angiographic images of the renal
arteries would in each case lead to a
moderate to large and often conclusive
shift in the probability that greater than
50% steno-occlusive disease is present.
A final consideration concerns the de-
tection of accessory renal arteries, which
are present in up to 25% of patients, that
originate above or below the main renal
artery. Overall, the three blinded off-site
readers of MR angiographic images de-
tected approximately 70% of the total
number of accessory arteries that were
detected on DSA images. Previously, MR
angiography has been associated with
comparatively poor visualization of acces-
sory renal arteries, as well as with lower
accuracy for the detection of potential
stenosis of accessory arteries compared
with that of conventional angiography
(56). However, there is some debate
about the clinical relevance of accessory
renal arteries and whether failure to de-
tect them has any effect on the utility of
noninvasive imaging for the detection of
renovascular hypertension (57). In our
Figure 5
Figure 5: Images in 71-year-old man with severe hypertension, arteriosclerosis, and angina pectoris.
(a)MIP coronal projection of CE MR angiographic acquisition (3.29/1.14) reveals inferior left and right acces-
sory renal arteries with severe stenosis (arrow) of inferior left accessory artery. (b)Angiographic image con-
firms accessory renal arteries and severe stenosis (arrow) of left accessory artery.
Table 3
Sensitivity, Specificity, Accuracy, PPV, NPV, and 95% CIs of CE MR Angiography for
Patient-Level Detection of Significant Steno-occlusive Disease of the Main Renal
Arteries Relative to DSA for Off-site Blinded Readers
Reader Sensitivity Specificity Accuracy PPV NPV
1 65.2 (57.9, 72.6) 86.5 (80.0, 93.1) 73.6 (68.3, 78.9) 88.2 (82.4, 94.0) 61.6 (53.8, 69.5)
2 78.9 (72.6, 85.2) 91.4 (86.1, 96.8) 83.8 (79.4, 88.3) 93.4 (89.2, 97.6) 73.8 (66.3, 81.4)
3 79.9 (73.6, 86.1) 81.3 (73.9, 88.7) 80.5 (75.7, 85.2) 86.4 (80.9, 91.9) 73.1 (65.1, 81.1)
Note.—Data are percentages. Numbers in parentheses are 95% CIs.
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study, some of the accessory renal ar-
teries not seen on CE MR angiographic
images may have been missed because
of a larger section thickness in use at
some of the 35 investigational centers.
A limitation of our study was that
parallel imaging technology and time-
resolved MR angiography were in their
infancy and not widely available at the
time the study was planned and con-
ducted. Therefore, the unavailability of
this more advanced MR technology
might have negatively affected image
quality, diagnostic performance, and
the detection of accessory renal arteries
compared with what is achievable with
state-of-the-art MR imaging systems to-
day (58). The increased imaging effi-
ciency provided by parallel imaging al-
lows increased temporal or spatial res-
olution and reduction of artifacts on CE
MR angiographic images (59). More-
over, increased spatial resolution or vol-
ume coverage can be achieved in a sin-
gle breath hold (eg, in renal CE MR
angiography) or in otherwise clinically
acceptable imaging durations (18,58,
59). Unfortunately, a drawback of par-
allel imaging techniques is an overall re-
duced signal-to-noise ratio. Because ga-
dobenate dimeglumine has been shown
to boost intravascular signal more than
other available gadolinium-based con-
trast agents (32,34,60,61), further
work should be performed to determine
whether the reduced signal-to-noise ra-
tio of more advanced sequences can be
compensated with the use of this con-
trast agent, particularly in vascular ter-
ritories for which increased speed
and/or spatial resolution is beneficial.
In conclusion, our study results con-
firm that gadobenate dimeglumine at a
dose of 0.1 mmol/kg is a safe gadolinium-
based contrast agent for use in CE MR
angiography of the renal arteries and pro-
vides an overall accuracy of 80%–87%
for the detection of significant steno-oc-
clusive disease.
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